|
 |
||||||||
 |
PRESS RELEASES ADVENTRX to Present at the 2005 San Diego Growth Conference on August 19 SAN DIEGO – August 17, 2005 – ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that management will present at the 2005 San Diego Growth Conference on Friday, August 19 at 9:00 a.m. Pacific Time. A link to the Company's live audio webcast will be available via the "Investors" section of the Company's Web site at www.adventrx.com/investors/events.htm. The link to the archived audio stream will be available for 14 days. The conference will be held at the Hilton La Jolla Torrey Pines in La Jolla, Calif. More information about the conference can be found at www.sdgrowth.com. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company's lead compound, CoFactor™ is a biomodulator of 5-fluororacil (5-FU), a widely used cancer chemotherapy. CoFactor met the primary endpoint for response and secondary endpoint for safety in an ongoing Phase II clinical trial. CoFactor is currently being tested with 5-FU in this US-based Phase II clinical trial and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor has received clearance under a special protocol assessment from the US FDA to begin a Phase III pivotal clinical trial for metastatic colorectal cancer. More information can be found on the Company's Web site at www.adventrx.com. Forward Looking Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last quarterly report on Form 10-Q, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
Contact:
ADVENTRX Pharmaceuticals Andrea Lynn 858-552-0866
Investor Contact:
Lippert Heilshorn & Associates Jody Cain (jcain@lhai.com) Brandi Floberg (bfloberg@lhai.com) 310-691-7100 |
